Salipro Biotech has announced that its patent entitled “Saposin lipoprotein particles and libraries from crude membranes” has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration.
The patents cover the company’s novel method of direct extraction of membrane proteins (DirectMX) from cells or crude membranes to enable drug development for challenging drug targets, as well as the generation of Salipro libraries representing the membrane proteome, the particles themselves and their use in drug discovery and membrane protein research, amongst others. The Salipro technology enables the development of novel therapeutics against drug targets that previously could not be investigated, states the company in a press release.
“An important corporate achievement”
The award of these patents further strengthens Salipro Biotech’s global intellectual property portfolio, with various patents already granted i.a. in the U.S., EU, China and Japan, according to the company.
“We are excited to announce the granting of these patents in the U.S. and in China. This news represents an important corporate achievement that fosters our position to accelerate drug discovery programs with pharma companies on challenging drug targets,” said Jens Frauenfeld, CEO, in the press release.